Mommox (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription to suppress the release of inflammatory cytokines and mediators. This anti‑inflammatory action decreases swelling, mucus production, and immune cell infiltration, providing symptom relief in allergic nasal conditions.

The specific dosing regimen for Mommox is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product label for the correct number of sprays per day.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mommox.

To order Mommox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Mommox (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency agents such as fluticasone propionate, mometasone may provide comparable symptom control with once‑daily dosing, but individual response and tolerability can vary.

Mommox should be stored at room temperature, below 25 °C, in its original packaging. Protect the spray from moisture and direct sunlight to maintain product stability. Do not freeze the container.

Mommox is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, adrenal suppression with prolonged use, cataracts or glaucoma, severe allergic reactions such as anaphylaxis, and opportunistic fungal infections of the nasal cavity. Patients should report any unusual symptoms to their healthcare provider promptly.

Mommox should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active nasal infections, recent nasal surgery, or those who have experienced severe adverse reactions to other intranasal corticosteroids.